Conditionally MYC:insights from novel transgenic models

Constadina Arvanitis, Dean W. Felsher*

*Corresponding author for this work

Research output: Contribution to journalShort survey

33 Citations (Scopus)

Abstract

MYC was one of the first oncogenes identified to be associated with chromosomal aberrations and one of the most common oncogenes involved in the pathogenesis of cancer. However, until recently it was not clear if MYC would be a good target for the treatment of cancer. New conditional transgenic models have been used to demonstrate that even the brief inactivation of MYC can reverse tumorigenesis. Here we review results from recent experimental model systems, which demonstrate that the inactivation of MYC may be a specific and effective treatment for many types of cancer.

Original languageEnglish (US)
Pages (from-to)95-99
Number of pages5
JournalCancer Letters
Volume226
Issue number2
DOIs
StatePublished - Aug 26 2005

Fingerprint

Oncogenes
Neoplasms
Chromosome Aberrations
Carcinogenesis
Theoretical Models

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Arvanitis, Constadina ; Felsher, Dean W. / Conditionally MYC:insights from novel transgenic models. In: Cancer Letters. 2005 ; Vol. 226, No. 2. pp. 95-99.
@article{8b456077542444ef88e0cec9c38370d1,
title = "Conditionally MYC:insights from novel transgenic models",
abstract = "MYC was one of the first oncogenes identified to be associated with chromosomal aberrations and one of the most common oncogenes involved in the pathogenesis of cancer. However, until recently it was not clear if MYC would be a good target for the treatment of cancer. New conditional transgenic models have been used to demonstrate that even the brief inactivation of MYC can reverse tumorigenesis. Here we review results from recent experimental model systems, which demonstrate that the inactivation of MYC may be a specific and effective treatment for many types of cancer.",
author = "Constadina Arvanitis and Felsher, {Dean W.}",
year = "2005",
month = "8",
day = "26",
doi = "10.1016/j.canlet.2004.10.043",
language = "English (US)",
volume = "226",
pages = "95--99",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

Conditionally MYC:insights from novel transgenic models. / Arvanitis, Constadina; Felsher, Dean W.

In: Cancer Letters, Vol. 226, No. 2, 26.08.2005, p. 95-99.

Research output: Contribution to journalShort survey

TY - JOUR

T1 - Conditionally MYC:insights from novel transgenic models

AU - Arvanitis, Constadina

AU - Felsher, Dean W.

PY - 2005/8/26

Y1 - 2005/8/26

N2 - MYC was one of the first oncogenes identified to be associated with chromosomal aberrations and one of the most common oncogenes involved in the pathogenesis of cancer. However, until recently it was not clear if MYC would be a good target for the treatment of cancer. New conditional transgenic models have been used to demonstrate that even the brief inactivation of MYC can reverse tumorigenesis. Here we review results from recent experimental model systems, which demonstrate that the inactivation of MYC may be a specific and effective treatment for many types of cancer.

AB - MYC was one of the first oncogenes identified to be associated with chromosomal aberrations and one of the most common oncogenes involved in the pathogenesis of cancer. However, until recently it was not clear if MYC would be a good target for the treatment of cancer. New conditional transgenic models have been used to demonstrate that even the brief inactivation of MYC can reverse tumorigenesis. Here we review results from recent experimental model systems, which demonstrate that the inactivation of MYC may be a specific and effective treatment for many types of cancer.

UR - http://www.scopus.com/inward/record.url?scp=22844444945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22844444945&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2004.10.043

DO - 10.1016/j.canlet.2004.10.043

M3 - Short survey

VL - 226

SP - 95

EP - 99

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -